Alternate-day dosing during buprenorphine treatment of opioid dependence
References (28)
- et al.
Addict. Behav.
(1979) - et al.
Drug. Alcohol. Depend.
(1993) Lancet
(1985)- et al.
Int. J. Addict.
(1978) JAMA
(1988)- et al.
The Effectiveness of Methadone Maintenance Treatment
(1991) - et al.
Clin. Pharmacol. Ther.
(1988) - et al.
JAMA
(1992) - et al.
NIDA Research Monograph no. 132, Problems of Drug Dependence 1992
- et al.
J. Pharmacol. Exp. Ther.
(1988)
NIDA Research Monograph no. 119 Problems of Drug Dependence 1991
Clin. Pharmacol. Ther.
Diagnostic and Statistical Manual of Mental Disorders (Third Edition, Revised)
Cited by (94)
Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers
2015, Drug and Alcohol DependenceCitation Excerpt :A recent meta-analysis (Dunn et al., 2011) of 28 BUP treatment trials that culminated with outpatient dose tapering found that participant retention was modest (median: 65%, range: 4–100%), while urinalysis-verified opioid abstinence was low during maintenance treatment (median: 41%, range: 1–94%), at the end of dose tapering (median: 30%, range: 22–41%), and at a post-taper follow-up assessment (median: 23%, range: 8–52%). Several methodological factors were associated with better outcomes of BUP dose tapering: higher pre-taper BUP maintenance dose (16–32 mg/day vs. <16 mg/day; Fareed et al., 2012), longer BUP maintenance (median: 5 days; range: 0–56; Dunn et al., 2011), longer dose taper (median: 17 days; range: 0–120; Dunn et al., 2011) and opioid-abstinent contingent reinforcement (Amass et al., 1994; Becker et al., 2001; Marsch et al., 2005; Greenwald, 2008). In addition, pre-treatment opioid use-related characteristics have been found to predict BUP maintenance and dose taper response in treatment-seeking opioid dependent individuals; specifically, older age at onset of opioid use (Soyka et al., 2008), shorter duration of continuous opioid use (Soyka et al., 2008), less frequent opioid use (Ziedonis et al., 2009; Warden et al., 2012; Hillhouse et al., 2013) and non-injection opioid use (Subramaniam et al., 2011) were related to positive BUP outcome (opioid-negative urine at follow-up or greater treatment retention, depending on the study).
Treatment of opioid-dependent pregnant women: Clinical and research issues
2008, Journal of Substance Abuse TreatmentCitation Excerpt :In randomized double-blind studies, dose increases during the course of pregnancy for both methadone and buprenorphine were an average of three-unit increases (totaling averages of 30 mg for methadone and 6 mg for buprenorphine; Jones et al., 2005). Although there has been considerable research investigating the parameters of buprenorphine dosing in nonpregnant patients (e.g., Amass, Bickel, Crean, Blake, & Higgins, 1998; Amass, Bickel, Higgins, & Badger, 1994; Amass, Kamien, & Mikulich, 2000, 2001; Bickel, Amass, Crean, & Badger, 1999; Greenwald, Schuh, Hopper, Schuster, & Johanson, 2002; Petry, Bickel, & Badger, 2000, 2001), similar research has not yet been conducted in pregnant patients. Given the extended biological half-life buprenorphine by virtue of slow dissociation from the mu receptor, blood volume changes with pregnancy might be less problematic than with methadone maintenance.
Buprenorphine Duration of Action: Mu-opioid Receptor Availability and Pharmacokinetic and Behavioral Indices
2007, Biological PsychiatryBuprenorphine treatment for opioid dependence: The relative efficacy of daily, twice and thrice weekly dosing
2005, Drug and Alcohol DependenceAcute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: A case report and review
2013, Pain Medicine (United States)Citation Excerpt :Additionally, buprenorphine dissociates slowly from mu-1 receptors [25], which accentuates this effect. These characteristics account for effective dosing as infrequently as every 48-hours [26,27,28]. There is insufficient data to determine an exact duration of action of buprenorphine, given its lipophilicity and depot-like action.
Buprenorphine Medication Versus Voucher Contingencies in Promoting Abstinence From Opioids and Cocaine
2009, Experimental and Clinical Psychopharmacology